BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29297942)

  • 21. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
    Enkhbat T; Nishi M; Takasu C; Yoshikawa K; Jun H; Tokunaga T; Kashihara H; Ishikawa D; Shimada M
    Anticancer Res; 2018 Jun; 38(6):3367-3373. PubMed ID: 29848685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of Foxp3 is associated with CD30 expression in the anaplastic large cell subtype of adult T-cell leukemia/lymphoma (ATLL) in US/Caribbean patients: potential therapeutic implications for CD30 antibody-mediated therapy.
    Yao J; Gottesman SR; Ayalew G; Braverman AS; Axiotis CA
    Am J Surg Pathol; 2013 Sep; 37(9):1407-12. PubMed ID: 23797717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma.
    Sun C; Jia Y; Wang W; Bi R; Wu L; Bai Q; Zhou X
    Histopathology; 2019 Mar; 74(4):618-628. PubMed ID: 30286249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer.
    Yang JH; Kim H; Roh SY; Lee MA; Park JM; Lee HH; Park CH; Lee HH; Jung ES; Lee SH; Lee YJ; Choi MH; Kim O; Kim IH
    Gastric Cancer; 2019 Jan; 22(1):147-154. PubMed ID: 29860599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
    Hayano A; Komohara Y; Takashima Y; Takeya H; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Yamanaka R
    Anticancer Res; 2017 Oct; 37(10):5655-5666. PubMed ID: 28982883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma.
    Komohara Y; Noyori O; Saito Y; Takeya H; Baghdadi M; Kitagawa F; Hama N; Ishikawa K; Okuno Y; Nosaka K; Seino KI; Matsuoka M; Suzu S
    J Clin Exp Hematop; 2018; 58(4):152-160. PubMed ID: 30541986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
    Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
    J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.
    Yanagihara T; Ikematsu Y; Kato K; Yonekawa A; Ideishi S; Tochigi T; Sugio T; Miyawaki K; Tanaka K; Harada E; Hamada N; Nakanishi Y
    Ann Hematol; 2018 Feb; 97(2):359-360. PubMed ID: 28967040
    [No Abstract]   [Full Text] [Related]  

  • 31. HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression.
    Bossard C; Bézieau S; Matysiak-Budnik T; Volteau C; Laboisse CL; Jotereau F; Mosnier JF
    Int J Cancer; 2012 Aug; 131(4):855-63. PubMed ID: 21953582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
    Albitar M; Johnson M; Do KA; Day A; Jilani I; Pierce S; Estey E; Kantarjian H; Keating M; Verstovsek S; O'brien S; Giles FJ
    Leukemia; 2007 Mar; 21(3):480-8. PubMed ID: 17215857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer.
    Wang Y; Lin J; Cui J; Han T; Jiao F; Meng Z; Wang L
    Oncotarget; 2017 Feb; 8(6):9354-9365. PubMed ID: 28030840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.
    Onishi A; Fuji S; Kitano S; Maeshima AM; Tajima K; Yamaguchi J; Kawashima I; Kawajiri A; Takemura T; Ito A; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Munakata W; Maruyama D; Tobinai K; Fukuda T
    Ann Hematol; 2022 Apr; 101(4):799-810. PubMed ID: 35032188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.
    Chang H; Jung WY; Kang Y; Lee H; Kim A; Kim HK; Shin BK; Kim BH
    Oncotarget; 2016 Dec; 7(49):80426-80434. PubMed ID: 27741514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
    Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
    J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aligning digital CD8
    Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
    Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.